Literature DB >> 55850

Gentamicin-resistant Pseudomonas aeruginosa and Serratia marcescens in a general hospital.

R D Meyer, R P Lewis, J Halter, M White.   

Abstract

From Aug. 1, 1974, to July 31, 1975, inclusive, 19-1% of Pseudomonas aeruginosa and 50-0% of Serratia marcescens isolates from a general hospital were gentamicin resistant as determined by standardised disc testing; 80% of 118 different clinical isolates showed minimum inhibitory concentrations larger than or equal to 16 mug/ml of gentamicin in agar-dilution testing. All gentamicin-resistant S. marcescens and 79% of Ps. aeruginosa isolates were susceptible to amikacin, while tobramycin and sisomicin were shown to have little advantage over gentamicin. A wide variety of immunotypes was found for Ps. aeruginosa, but only two predominant types were found for S. marcescens. Most isolates originated from the urinary tract, but nine which came from urine or wounds were also isolated from blood. Resistant strains seemed to be as virulent as sensitive strains. A common source was not found. Clinical improvement was noted in 13 of 17 patients treated with amikacin. The high frequency of gentamicin resistance is a continuing problem in this hospital and soon may be in others.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 55850     DOI: 10.1016/s0140-6736(76)90370-6

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  26 in total

1.  Polymyxin B and rifampin: new regimen for multiresistant Serratia marcescens infections.

Authors:  R C Ostenson; B T Fields; C M Nolan
Journal:  Antimicrob Agents Chemother       Date:  1977-12       Impact factor: 5.191

2.  In vitro activity of netilmicin compared with gentamicin, tobramycin, amikacin, and kanamycin.

Authors:  T C Eickhoff; J M Ehret
Journal:  Antimicrob Agents Chemother       Date:  1977-05       Impact factor: 5.191

3.  Emergence in a burn center of populations of bacteria resistant to gentamicin, tobramycin, and amikacin: evidence for the need for changes in zone diameter interpretative standards.

Authors:  B H Minshew; H M Pollock; F D Schoenknecht; J C Sherris
Journal:  Antimicrob Agents Chemother       Date:  1977-12       Impact factor: 5.191

4.  In vitro synergistic activities of aminoglycosides and new beta-lactams against multiresistant Pseudomonas aeruginosa.

Authors:  H Giamarellou; N P Zissis; G Tagari; J Bouzos
Journal:  Antimicrob Agents Chemother       Date:  1984-04       Impact factor: 5.191

5.  In vitro susceptibility of gentamicin-resistant Enterobacteriaceae and Pseudomonas aeruginosa to netilmicin and selected aminoglycoside antibiotics.

Authors:  R D Meyer; L L Draus; K A Pasieczinik
Journal:  Antimicrob Agents Chemother       Date:  1976-10       Impact factor: 5.191

6.  Nosocomial infection with gentamicin-carbenicillin-resistant Pseudomonas aeruginosa.

Authors:  I M Baird; J M Slepack; C A Kauffman; J P Phair
Journal:  Antimicrob Agents Chemother       Date:  1976-10       Impact factor: 5.191

7.  Comparison of the nephrotoxicity and auditory toxicity of tobramycin and amikacin.

Authors:  J M Gatell; J G San Miguel; L Zamora; V Araujo; M Bonet; M Bohé; M T Jimenez de Anta; M Farré; M Elena; A Ballesta; J L Marin
Journal:  Antimicrob Agents Chemother       Date:  1983-06       Impact factor: 5.191

8.  Epidemic outbreak of Serratia marcescens infection in a cardiac surgery unit.

Authors:  I Wilhelmi; J C Bernaldo de Quirós; J Romero-Vivas; J Duarte; E Rojo; E Bouza
Journal:  J Clin Microbiol       Date:  1987-07       Impact factor: 5.948

9.  Gentamicin use and Pseudomonas and Serratia resistance: effect of a surgical prophylaxis regimen.

Authors:  N J Roberts; R G Douglas
Journal:  Antimicrob Agents Chemother       Date:  1978-02       Impact factor: 5.191

10.  In vitro studies with netilmicin compared with amikacin, gentamicin, and tobramycin.

Authors:  V Dhawan; E Marso; W J Martin; L S Young
Journal:  Antimicrob Agents Chemother       Date:  1977-01       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.